However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the vast array of E3 ligases in the human genome have been explored in the TPD field. Dr.

Shanghai Helioson Pharmaceutical Co. Ltd. has synthesized molecular glue degraders comprising an E3 ubiquitin ligase coupled to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A ...